Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.0272 | 0.5 | 0.5 |
Treponema pallidum | ATP-dependent RNA helicase | 0.0272 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0272 | 0.5 | 0.5 |
Giardia lamblia | Translation initiation factor eIF-4A, putative | 0.0272 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0272 | 0.5 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0272 | 0.5 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0272 | 0.5 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A III | 0.0272 | 0.5 | 0.5 |
Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.0272 | 0.5 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A | 0.0272 | 0.5 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0272 | 0.5 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A III | 0.0272 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.0272 | 0.5 | 0.5 |
Onchocerca volvulus | Eukaryotic initiation factor 4A homolog | 0.0272 | 0.5 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0272 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0272 | 0.5 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0272 | 0.5 | 0.5 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0272 | 0.5 | 0.5 |
Entamoeba histolytica | DEAD/DEAH box helicase, putative | 0.0272 | 0.5 | 0.5 |
Plasmodium vivax | RNA helicase-1, putative | 0.0272 | 0.5 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0272 | 0.5 | 0.5 |
Plasmodium falciparum | eukaryotic initiation factor 4A | 0.0272 | 0.5 | 0.5 |
Echinococcus granulosus | eukaryotic initiation factor 4A | 0.0272 | 0.5 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.